IO Biotech Management

Management criteria checks 1/4

IO Biotech's CEO is MBZ Zocca, appointed in Jan 2015, has a tenure of 9.83 years. total yearly compensation is $1.65M, comprised of 32.9% salary and 67.1% bonuses, including company stock and options. directly owns 0.097% of the company’s shares, worth $47.85K. The average tenure of the management team and the board of directors is 1.6 years and 3.1 years respectively.

Key information

MBZ Zocca

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage	32.9%
CEO tenure	9.8yrs
CEO ownership	0.1%
Management average tenure	1.6yrs
Board average tenure	3.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has MBZ Zocca's remuneration changed compared to IO Biotech's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$90m
Jun 30 2024	n/a	n/a	-US$88m
Mar 31 2024	n/a	n/a	-US$88m
Dec 31 2023	US$2m	US$541k	-US$86m
Sep 30 2023	n/a	n/a	-US$80m
Jun 30 2023	n/a	n/a	-US$74m
Mar 31 2023	n/a	n/a	-US$71m
Dec 31 2022	US$734k	US$515k	-US$71m
Sep 30 2022	n/a	n/a	-US$74m
Jun 30 2022	n/a	n/a	-US$65m
Mar 31 2022	n/a	n/a	-US$87m
Dec 31 2021	US$8m	US$399k	-US$75m
Sep 30 2021	n/a	n/a	-US$56m
Jun 30 2021	n/a	n/a	-US$54m
Mar 31 2021	n/a	n/a	-US$17m
Dec 31 2020	US$409k	US$307k	-US$15m

Compensation vs Market: MBZ's total compensation ($USD1.65M) is above average for companies of similar size in the US market ($USD646.00K).

Compensation vs Earnings: MBZ's compensation has increased whilst the company is unprofitable.

CEO

MBZ Zocca (57 yo)

9.8yrs

Tenure

US$1,645,088

Compensation

Dr. Mai-Britt Zocca, Ph D, also known as MBZ, was also the Founder and Chief Executive Officer of Onconox ApS since July 2011 until May 2019. She served as Director at Valo Therapeutics Ltd since June 2020...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mai-Britt Zocca	Founder	9.8yrs	US$1.65m	0.097% $ 47.8k
Devin Smith	Secretary	1.8yrs	US$917.30k	0.0075% $ 3.7k
Qasim Ahmad	Chief Medical Officer	1.3yrs	US$920.76k	no data
Inge Svane	Founder & Clinical Advisor	no data	no data	no data
Mads Andersen	Co-Founder & Scientific Advisor	no data	no data	no data
Anders Ljungqvist	Founder	no data	no data	no data
Per Straten	Founder	no data	no data	no data
Amy Sullivan	Chief Financial Officer	2.1yrs	US$904.15k	0.11% $ 55.6k
Eric Faulkner	Chief Technical Officer	1.3yrs	no data	no data
Daniel Mannix	Senior Vice President of Regulatory Affairs	2.8yrs	no data	no data
Faical Miyara	Chief Business Officer	less than a year	no data	no data
Marjan Shamsaei	Senior VP of Commercial Development & Portfolio Lead	less than a year	no data	no data

1.6yrs

Average Tenure

54.5yo

Average Age

Experienced Management: IOBT's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Mai-Britt Zocca	Founder	3.1yrs	US$1.65m	0.097% $ 47.8k
Inge Svane	Founder & Clinical Advisor	no data	no data	no data
Mads Andersen	Co-Founder & Scientific Advisor	no data	no data	no data
David Smith	Independent Director	2.8yrs	US$124.17k	0% $ 0
K. Hirth	Independent Chairman	8.2yrs	US$145.75k	0% $ 0
Christian Elling	Independent Director	8.9yrs	US$114.14k	0% $ 0
Kathleen Glaub	Independent Director	6.5yrs	US$133.00k	0% $ 0
Alexander Maximiliaan Eggermont	Sr. Clinical Advisor & Member of the Scientific Advisory Board	no data	no data	no data
Kapil Dhingra	Strategic Advisory Board Member	no data	no data	no data
Helen Collins	Independent Director	less than a year	US$52.48k	0% $ 0
Heidi Hunter	Independent Director	1.3yrs	US$112.61k	0% $ 0

3.1yrs

Average Tenure

64.5yo

Average Age

Experienced Board: IOBT's board of directors are considered experienced (3.1 years average tenure).

IO Biotech Management

Management criteria checks 1/4

Key information

Recent management updates

IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors

IO Biotech, Inc., Annual General Meeting, Jun 06, 2024

IO Biotech Announces Marjan Shamsaei as Senior Vice President

IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer

High number of new directors

IO Biotech Appoints Helen Collins, Md, to Its Board of Directors

Recent updates

IO Biotech, Inc. Announces Data from the NSCLC Cohort in the Phase 2 Basket Trial of IO102-IO103

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-Line Treatment of Advanced Head and Neck Cancer

Price target decreased by 13% to US$8.50

IO Biotech, Inc. Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

New major risk - Financial position

New minor risk - Share price stability

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors

IO Biotech, Inc., Annual General Meeting, Jun 06, 2024

New minor risk - Market cap size

IO Biotech Announces Marjan Shamsaei as Senior Vice President

IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103

IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer

IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting

New major risk - Revenue and earnings growth

New minor risk - Market cap size

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

High number of new directors

IO Biotech Appoints Helen Collins, Md, to Its Board of Directors

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

New minor risk - Share price stability

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Price target decreased by 15% to US$9.67

IO Biotech, Inc. Appoints Heidi Hunter to Its Board of Directors

IO Biotech, Inc. announced that it expects to receive $75.057935 million in funding from a group of investors

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer Center

IO Biotech, Inc. Announces Executive Changes

New minor risk - Share price stability

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech, Inc. Appoints Christine Richter as Senior Vice President, Commercial and Program Lead

Chief Financial Officer recently bought US$58k worth of stock

IO Biotech Appoints Devin Smith as General Counsel and Chief Compliance Officer

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Price target decreased to US$17.50

IO Biotech, Inc. Announces Appointment of Amy Sullivan as Chief Financial Officer

IO Biotech names new CFO

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech GAAP EPS of -$0.64

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma

IO Biotech, Inc. Announces Executive Changes

High number of new directors

High number of new directors

IO Biotech, Inc. Announces its Two Directors Not Stand for Re-Election

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

IO Biotech, Inc. Announces Appointment of David V. Smith to Board of Directors

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age